Mode
Text Size
Log in / Sign up

Self-directed CBT-CP reduces pain interference by 0.98 points compared to clinician-delivered CBT-CPSelf-directed therapy shows promise for chronic musculoskeletal pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider self-directed CBT-CP as a viable alternative to clinician-delivered CBT for chronic musculoskeletal pain.

This randomized clinical trial evaluated the efficacy of self-directed cognitive behavioral therapy for chronic pain (CBT-CP) compared to clinician-delivered CBT-CP in a large cohort of patients. The study was conducted across 9 US Veterans Health Administration (VHA) health care systems. The study population consisted of 764 patients diagnosed with chronic musculoskeletal pain. The primary objective was to determine if a self-directed format could achieve comparable or superior outcomes to traditional clinician-led sessions in a pragmatic setting.

The intervention group received self-directed CBT-CP, which consisted of 11 weeks of treatment featuring weekly personalized audio-recorded feedback. The comparator group received clinician-delivered CBT-CP, which consisted of 4 to 11 weekly sessions. This design allowed for a direct comparison of the delivery method's impact on patient outcomes over a period of 12 months.

The primary outcome was patient-reported pain interference, measured by the BPI-I subscale. At the 4-month follow-up, self-directed CBT-CP was superior to clinician-delivered CBT-CP. The mean difference was -0.98, with the self-directed group scoring 5.26 compared to 6.23 in the clinician-delivered group. This result was statistically significant with a 95% CI of -1.31 to -0.65 and a p-value of less than.001. At the 6-month and 12-month follow-up marks, the self-directed CBT-CP group maintained its superiority over the clinician-delivered group, although specific mean differences and confidence intervals for these later time points were not reported.

Secondary outcomes at 4 months included pain intensity, pain impact, catastrophizing, self-efficacy, sleep, global impression of change, and depressive symptoms. The study found that self-directed CBT-CP was superior to clinician-delivered CBT-CP across these secondary outcomes, with results described as small to moderate improvements (p ≤.001). Additionally, the study assessed treatment dose, finding that participants in the self-directed CBT-CP group completed more expected treatment sessions than those in the clinician-delivered group.

Safety and tolerability data were not reported in the study results. Specific rates for adverse events, serious adverse events, or treatment discontinuations were not provided. Consequently, the tolerability of the self-directed format compared to the clinician-delivered format cannot be quantified.

These results provide evidence for the efficacy of self-directed CBT-CP in a large, real-world veteran population. While the study is a randomized, open-label pragmatic superiority trial, the results suggest that self-directed models may be a viable alternative to clinician-delivered models. The findings indicate that self-directed CBT-CP may be an effective alternative to clinician-delivered CBT that could increase the uptake of CBT-CP in clinical practice.

Methodological limitations include the open-label nature of the trial and the lack of reported data for specific secondary outcome values at 6 and 12 months. Furthermore, the study does not provide specific data on the rate of adverse events or the specific reasons for any potential dropouts. These limitations should be considered when interpreting the strength of the evidence for long-term adoption.

Clinically, these results suggest that for patients with chronic musculoskeletal pain, a self-directed CBT-CP program may offer a comparable or superior experience to clinician-delivered sessions. This could be particularly useful in settings where clinician availability is limited. However, the improvements in pain interference were described as modest. Questions remain regarding the specific magnitude of improvement in secondary outcomes like sleep and depressive symptoms, as only qualitative descriptors were provided for these metrics.

Living with chronic musculoskeletal pain can be incredibly difficult. It often affects a person's ability to work, move freely, and enjoy daily activities. Because of these challenges, many people look for ways to manage their pain and improve their quality of life. This research focuses on a specific type of therapy called CBT-CP, which helps patients change how they think about and manage their physical pain.

To test this approach, researchers conducted a randomized clinical trial involving 764 patients with chronic musculoskeletal pain. The study took place across nine different health systems. The participants were split into two groups. One group received a clinician-delivered version of the therapy, which involved several sessions with a healthcare professional. The other group used a self-directed version of the same therapy. This self-directed version consisted of 11 weeks of treatment using personalized audio-recorded feedback.

The results showed that the self-directed program was more effective than the clinician-delivered version at reducing pain interference. Pain interference is a measure of how much pain stops a person from doing their normal daily activities. At the four-month mark, those using the self-directed audio program reported lower levels of interference than those who met with a clinician. This advantage remained consistent at the six-month and 12-month follow-up points. Additionally, the self-directed group showed small to moderate improvements in other areas, such as pain intensity, sleep quality, and feelings of self-efficacy. The study also noted that people in the self-directed group were more likely to complete all their scheduled sessions.

While these results are encouraging, it is important to keep a few things in mind. The improvements in pain interference were described as modest, and the improvements in other areas were small to moderate. Because this was a single trial, it does not mean that every patient will have the same experience. The study did not report any specific safety concerns or adverse events, but it is always important to work with a healthcare provider to determine the best plan for your specific needs. For patients right now, this research suggests that self-directed programs could be a practical and effective way to manage chronic pain. For some people, a self-directed audio program might be easier to access or more convenient than attending multiple in-person appointments. While it is not a replacement for medical advice, it shows that technology-based tools can be a powerful way to manage the daily impact of musculoskeletal pain.

What this means for you:
Self-directed audio therapy may be more effective than clinician-led sessions for reducing pain interference.

Study Details

Study typeRct
Sample sizen = 764
EvidenceLevel 2
Follow-up2.5 mo
PublishedAug 2026
View Original Abstract ↓
IMPORTANCE: Cognitive behavioral therapy for chronic pain (CBT-CP) is a first-line nonpharmacological treatment, but uptake remains low due to multiple access barriers. OBJECTIVE: To assess the effectiveness of self-directed CBT-CP with asynchronous, personalized feedback relative to clinician-delivered CBT-CP under usual clinical practice conditions. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label pragmatic superiority trial enrolled 764 patients with chronic musculoskeletal pain from 9 US Veterans Health Administration (VHA) health care systems from December 20, 2019, to February 20, 2024; follow-up was completed in February 2025. INTERVENTIONS: Participants were allocated 1:1 to self-directed CBT-CP (n = 384) or clinician-delivered CBT-CP (n = 380). The self-directed group included 11 weeks of treatment with weekly personalized audio-recorded feedback provided by coaches. Feedback was based on participants' daily reports of pain coping skill practice, physical activity, and pain-relevant ratings collected by the interactive voice response system. Clinician-delivered CBT-CP included 4 to 11 weekly sessions provided under usual practice conditions. MAIN OUTCOMES AND MEASURES: The primary outcome was patient-reported pain interference measured by the 7-item Brief Pain Inventory-Interference (BPI-I) subscale at 4 months (score range, 0-10; higher scores indicate worse function; minimum clinically important difference, 1). Secondary outcomes included BPI-I at 6 and 12 months; pain intensity, pain impact, catastrophizing, self-efficacy, sleep, global impression of change, depressive symptoms (all at 4 months); and treatment dose. RESULTS: Of the 764 randomized participants (mean age, 52.8 [SD, 12.3] years; 299 women [39.1%]; 289 Black [39.1%]; 399 White [54.0%]; and 107 Hispanic ethnicity [14.0%] and 186 participants [24%] who resided in a rural area), 583 participants (76%) completed the 4-month assessment and 523 (68%) the 12-month assessment. At 4 months, the self-directed CBT-CP was superior to clinician-delivered CBT-CP for reduction in pain interference (mean score, 5.26 vs 6.23, respectively; mean difference, -0.98; 95% CI, -1.31 to -0.65, P < .001) and maintained superiority at 6 and 12 months. Self-directed CBT-CP was superior to clinician-delivered CBT-CP for all other outcomes at 4 months (P ≤ .001). Participants in the self-directed CBT-CP group completed more expected treatment sessions than patients in the clinician-delivered CBT-CP group. CONCLUSIONS AND RELEVANCE: Self-directed CBT-CP was associated with modest improvements in pain interference at 4 months that were sustained to 12 months, small to moderate improvements in all secondary outcomes at 4 months, and higher session-completion rates, relative to clinician-delivered CBT-CP. Scalable, convenient self-directed CBT may be an effective alternative to clinician-delivered CBT that could increase uptake of CBT-CP. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03469505.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.